PXT3003 regulatory update

FDA and the European Commission granted Orphan Drug designation to PXT3003 to treat Charcot-Marie-Tooth (CMT) disease Type IA. The product - a low-dose combination of baclofen, naltrexone and D-sorbitol - is expected to start Phase III testing at year end. ...